NIH GETS DIRECTOR — The Senate voted 62-36 on Tuesday to confirm Dr. Monica Bertagnolli to lead the National Institutes of Health, POLITICO’s Erin Schumaker and Kelly Hooper report. Nearly every Democrat joined 13 Republicans in filling the post responsible for overseeing billions in federal research grants, which has been vacant since Dr. Francis Collins left nearly two years ago. While Bertagnolli won confirmation with ease, her road there was rocky. After President Joe Biden tapped her to lead NIH in May, Sen. Bernie Sanders (I-Vt.) held up her nomination for months in an effort to extract a comprehensive plan to lower drug prices from the White House. He and Pennsylvania Sen. John Fetterman were the only members of the Democratic caucus to vote against confirmation. Thirty-four Republicans also voted no. During her confirmation hearing last month, Sanders and ranking member Bill Cassidy (R-La.) pressed Bertagnolli on her approach to drug pricing and whether she’d add reasonable pricing clauses to NIH contracts. She told both members she couldn’t commit to any particular drug pricing policy. LACKING TRIAL DIVERSITY — Few clinical trials report the race and ethnicity of their participants in their study results, reports the Milken Institute. Why it matters: During her HELP Committee hearing last month, Bertagnolli pledged to make clinical trials, which are registered by the NIH, more inclusive. But among more than 21,000 clinical trials registered with ClinicalTrials.gov as of May 2022 that have reported results, race was reported only half of the time and ethnicity only a quarter of the time. Most studies reported gender. The gaps, the researchers said, could lead to disparities in quality of care because therapies have been based on incomplete information for understudied groups. Among the clinical trials that reported demographic information, including trials that haven’t yet posted results, researchers found: — 52.4 percent were women. — 30.2 percent were Hispanic and 69.8 percent were non-Hispanic, with some variation depending on the type of trial. — 75.1 percent were white, 16.6 percent were Black, 6 percent were Asian and 2.2 percent were listed as another race. PEPFAR HOLD-UP — State Department officials warn that questions from Congress regarding abortion as a method of family planning — sent in response to congressional notifications for 2024 global HIV spending — are holding up funding for AIDS relief and that the delay could harm efforts to fight the disease, Carmen reports. But the department has been unclear in correspondence with Congress, seen by POLITICO, about when it needs the funds appropriated for the President’s Emergency Plan for AIDS Relief released to avoid those harms. Emails from State Department officials to the House Foreign Affairs Committee in September didn’t specify a deadline, and John Nkengasong, U.S. global AIDS coordinator, didn’t provide one during a panel discussion at the Milken Future of Health Summit in Washington on Tuesday. “We don’t have a fixed deadline for that, but we were supposed to have moved those monies to the field so that they meet the needs,” Nkengasong said. The State Department didn’t immediately respond to a request for comment. How we got here: House Foreign Affairs Chair Michael McCaul (R-Texas) and the State Department have blamed each other for a delay in dispensing $2 billion in funding to international groups fighting HIV and AIDS. McCaul’s staff has asked for revisions to program documents to indicate that PEPFAR doesn’t fund programs that promote abortion as a family-planning method.
|
Comments
Post a Comment